Investors in MannKind Corp (Symbol: MNKD) saw new options begin trading today, for the August 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for …
NASDAQ · 7/2/2015
We all know the obvious reasons not to quite love MannKind (MNKD). For instance, MannKind stock lost more than 40% in the past year while the S&P 500 gained around 8%. Then there’s the initial sales results of …
Investor Place · 6/23/2015
MannKind Stock
This could soon be a huge catalyst driving Afrezza prescriptions across the US. MNKD stock has passed below its 200 day moving average of $5.55 this week. This reflects sentiment towards the minimal sales data available to analysts. One year ago ...
Seeking Alpha · 7/2/2015
Mannkind Investor
More from Bing News
MannKind Corporation (MNKD) stock has been all over the place in the last six months, and it looks like the volatility will continue, at least for now. The great debate is whether the drug maker's only product on the …
Value Walk · 6/24/2015
MannKind (NASDAQ:MNKD) opened at 5.69 on Wednesday. MannKind has a 52-week low of $3.46 and a 52-week high of $10.26. The stock has a 50-day moving average of $5.39 and a 200-day moving average of $5.55. The company’s market cap is $2.
Ticker Report · 7/1/2015
RBC Capital reiterated their outperform rating on shares of MannKind (NASDAQ:MNKD) in a research report released on Thursday morning. RBC Capital currently has a $10.00 price objective on the biopharmaceutical company’s stock. MannKind … · 6/25/2015
MannKind Corp. (MNKD)’s monthly performance stand at 11.92% and has an analyst rating of 2.6 (Click To Expand Current Stock Data:) Opko Health, Inc. (OPK) of the Healthcare sector (Biotechnology) is down -0. · 6/29/2015
The past two months have brought about some very turbulent times for MannKind (NASDAQ: MNKD) shareholders ... Deepak maintained his buy rating on the stock, with a $9 price target, implying upside of more than …
Investopedia · 7/1/2015
With this in mind, let's consider if Adaptimmune Therapeutics (NASDAQ: ADAP ) and MannKind Corp. (NASDAQ: MNKD ) might be good contrarian buys ... the Street is extremely negative on this stock. Specifically …
The Motley Fool · 6/24/2015
Gilead Sciences Inc. (NASDAQ:GILD) [Detail Analytic Report] stock shows 50% growth in its price over the ... MannKind Corp. (NASDAQ:MNKD) [Detail Analytic Report] has received upgraded ratings by its pool of … · 6/25/2015